ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Could an old Amgen-developed RA drug make CAR-T treatments safer?
fiercebiotech
June 11, 2018The personalized CAR-T cells that are FDA-approved to treat blood cancers, Gilead’s Yescarta and Novartis’s Kymriah, can raise the risk of a side effect that has been challenging to prevent and treat: cytokine release syndrome (CRS).
Pharma Sources Insight January 2025
